title: Multinational Internet-based survey of patient preference for newer oral or injectable Type 2 diabetes medication.
abstract: BACKGROUND
  The prevalence of Type 2 diabetes mellitus continues to rise. Although glucagon-like peptide-1 (GLP-1) analog and dipeptidyl peptidase-4 (DPP-4) inhibitor medications are effective, there are differences between these products, including method of administration (injectable versus oral). The objective of this study was to examine patient preferences (and predictors of preferences) for two different medication profiles, one similar to a GLP-1 analog (liraglutide) and another similar to a DPP-4 inhibitor (sitagliptin).
  
  
  METHODS
  Internet survey data were collected in two waves (wave 1, n = 2402; wave 2, n = 1340) using patients from the US and Europe. Patients were presented with two hypothetical medication profiles ("drug A" and "drug B", resembling sitagliptin and liraglutide, respectively) and asked to report their preferences.
  
  
  RESULTS
  Most patients in wave 1 and wave 2 reported that overall they would prefer a drug with the sitagliptin-like profile (81.9% and 84.4%, respectively) over a drug with the liraglutide-like profile (18.1% and 15.6%, respectively), and >80% of patients reported that they would be able to take a drug with the sitagliptin-like profile as directed by their physician for a longer period. The likelihood of preferring the sitagliptin-like profile significantly increased as age (odds ratio [OR] = 1.02) and importance placed on method of administration (OR = 1.32) increased (P < 0.05). Although the sitagliptin-like profile was preferred by the majority of patients in all subgroups, a lower proportion of patients with obesity, with weight gain, with A1C values above target, and who exercised preferred the sitagliptin-like profile compared with those without obesity (77.0% versus 87.9%), without weight gain (77.8% versus 86.7%), with A1C values at or below target (79.0% versus 86.5%), and who did not exercise (81.6% versus 86.4%), respectively (P < 0.05).
  
  
  CONCLUSIONS
  This research suggests that patients (across geographies) prefer an oral medication with a profile resembling sitagliptin to an injectable medication with a profile resembling liraglutide.
authors.affiliation: Health Sciences Practice, Kantar Health, New York;
authors.forename: Marco Dacosta
authors.initials: MD
authors.lastname: Dibonaventura
authors.forename: Jan-Samuel
authors.initials: JS
authors.lastname: Wagner
authors.forename: Cynthia J
authors.initials: CJ
authors.lastname: Girman
authors.forename: Kimberly
authors.initials: K
authors.lastname: Brodovicz
authors.forename: Qiaoyi
authors.initials: Q
authors.lastname: Zhang
authors.forename: Ying
authors.initials: Y
authors.lastname: Qiu
authors.forename: Sri-Ram
authors.initials: SR
authors.lastname: Pentakota
authors.forename: Larry
authors.initials: L
authors.lastname: Radican